Figure 3.
Cumulative incidence of CNS relapse stratified by CITI risk group. Cumulative incidence of CNS relapse in training set (A) and validation set (B) is depicted by reverse Kaplan-Meier curve, stratified by CITI risk group. Reverse Kaplan-Meier curve for validation set without scaled y-axis is shown in top-left panel inset. For all Kaplan-Meier curves, hashmarks denote censored patients, and shading indicates 95% CI. Log-rank P values for trend are shown above the Kaplan-Meier curves. Cumulative risk, HRs with 95% CI, and Holm-Bonferroni adjusted P values for pairwise risk group comparisons are depicted in tables beneath Kaplan-Meier curves. Low-risk groups were used as reference values for training and validation sets.

Cumulative incidence of CNS relapse stratified by CITI risk group. Cumulative incidence of CNS relapse in training set (A) and validation set (B) is depicted by reverse Kaplan-Meier curve, stratified by CITI risk group. Reverse Kaplan-Meier curve for validation set without scaled y-axis is shown in top-left panel inset. For all Kaplan-Meier curves, hashmarks denote censored patients, and shading indicates 95% CI. Log-rank P values for trend are shown above the Kaplan-Meier curves. Cumulative risk, HRs with 95% CI, and Holm-Bonferroni adjusted P values for pairwise risk group comparisons are depicted in tables beneath Kaplan-Meier curves. Low-risk groups were used as reference values for training and validation sets.

Close Modal

or Create an Account

Close Modal
Close Modal